Axsome Therapeutics Company Profile (NASDAQ:AXSM)

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. View Axsome Therapeutics' Earnings History.

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Axsome Therapeutics.

5 brokerages have issued 1 year target prices for Axsome Therapeutics' stock. Their predictions range from $13.00 to $31.00. On average, they expect Axsome Therapeutics' share price to reach $19.60 in the next year. View Analyst Ratings for Axsome Therapeutics.

Here are some recent quotes from research analysts about Axsome Therapeutics stock:

• 1. According to Zacks Investment Research, "Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. " (7/13/2017)
• 2. Aegis analysts commented, "We believe Ms. Potter’s prior experience adds value to the Board of Directors for Axsome. Her career in healthcare spans more than 30 years with multiple leadership positions at several large pharmaceutical companies. As Axsome looks to report multiple phase III interim analysis and topline readouts over the next 24 months, her experience in the commercialization process should go a long way for management. Myrtle Potter – Prior experience. After starting her career with Procter and Gamble Patient Care Products, Ms. Potter went on to spend 14 years of her early career at Merck & Co. While holding positions of increasing responsibility at Merck, she started Astra Merck, a joint venture entity that later became AstraZeneca, and served as Vice President of Merck’s US pharmaceutical business unit with about $800 mil revenue. Ms. Potter also served as President of Bristol-Myers Squibb’s US Cardiovascular and Metabolic Business – a 3,500 person business segment with $3.5 billion annual revenue – for 4 years. From 2000 to 2005 she was President, Commercial Operations and Chief Operating Officer at Genentech. While at Genentech, Ms. Potter led the commercialization of a long list of products: Herceptin, Tarceva, Xolair, Avastin, Rituxan, Nutropin, Activase, and TNkase." (6/20/2017)

Some companies that are related to Axsome Therapeutics include Catalyst Pharmaceuticals (CPRX), UROGEN PHARMA (URGN), ObsEva SA (OBSV), Ardelyx (ARDX), Pieris Pharmaceuticals (PIRS), uniQure N.V. (QURE), Chimerix (CMRX), Immune Design Corp. (IMDZ), Madrigal Pharmaceuticals (MDGL), Kindred Biosciences (KIN), Athersys (ATHX), Zymeworks (ZYME), Stemline Therapeutics (STML), Faron Pharmaceuticals Oy (FARN), Cascadian Therapeutics (CASC), AILERON THERAP (ALRN), Clearside Biomedical (CLSD) and Kura Oncology (KURA).

Axsome Therapeutics' management team includes the folowing people:

• Herriot Tabuteau M.D., Chairman of the Board, Chief Executive Officer
• John Golubieski, Chief Financial Officer
• Constance Ames, Vice President - Finance
• Mark Jacobson, Senior Director - Operations
• Randall E. Kaye M.D., Chief Medical Officer
• Robert Niecestro Ph.D., Head of Regulatory
• Mark Coleman M.D., Independent Director
• Roger A. Jeffs Ph.D., Independent Director
• Myrtle S. Potter, Independent Director
• Mark Saad, Independent Director

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.38%), JPMorgan Chase & Co. (6.08%), Royce & Associates LP (3.73%), Sphera Funds Management LTD. (2.12%), Stifel Financial Corp (1.76%) and Vanguard Group Inc. (1.17%). View Institutional Ownership Trends for Axsome Therapeutics.

Axsome Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Northern Trust Corp, Vanguard Group Inc., FMR LLC and Mariner Wealth Advisors LLC. View Insider Buying and Selling for Axsome Therapeutics.

Axsome Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., LMR Partners LLP, Goldman Sachs Group Inc. and Susquehanna International Group LLP. View Insider Buying and Selling for Axsome Therapeutics.

Shares of Axsome Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Axsome Therapeutics stock can currently be purchased for approximately $5.00.